The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
People with a high body weight living in England can now access subsidised weight-loss drugs to treat their obesity.
Irish Examiner on MSN3d
On the rebound: What are the long-term risks of Ozempic?Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Sales of Novo Nordisk’s fast-growing GLP ... even further by new outcomes data showing that Ozempic can reduce the risk of chronic kidney disease in patients with type 2 diabetes, while Wegovy ...
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Novo Nordisk has accused Singapore ... including GLP-1 agonist Ozempic (semaglutide), which was approved to lower the risk of worsening kidney disease and cardiovascular death in CKD patients ...
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
Novo Nordisk A/S (NYSE:NVO) is a manufacturer, researcher & developer, and distributor of pharmaceutical products. It operates through rare disease and diabetes and obesity Care segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback